Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVAC-RCC-001: Personalized Neoantigen Vaccine in Advanced Renal Cell Carcinoma
NCT05641545Phase 1Terminated
- Sponsor
- SLK-Kliniken Heilbronn
- Start
- Oct 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IVAC in renal cell carcinoma (RCC), sponsored by SLK-Kliniken Heilbronn. Primary endpoint: Success of treatment at 120 days. Started Oct 2022; status: terminated.
02
Drugs
IVAC
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05641545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05641545.